» Articles » PMID: 29312797

Loss of ACVRIB Leads to Increased Squamous Cell Carcinoma Aggressiveness Through Alterations in Cell-cell and Cell-matrix Adhesion Proteins

Overview
Journal Am J Cancer Res
Specialty Oncology
Date 2018 Jan 10
PMID 29312797
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Squamous cell carcinomas of the head and neck (HNSCC) and esophagus (ESCC) pose a global public health issue due to high mortality rates. Unfortunately, little progress has been made in improving patient outcomes. This is partially a result of a lack of understanding the mechanisms that drive SCC progression. Recently, Activin A signaling has been implicated in a number of cancers, yet the role of this pathway in SCC remains poorly understood. We have previously discovered that the Activin A ligand acts as a tumor suppressor when epithelial Activin receptor type IB (ACVRIB) is intact; however, this effect is lost upon ACVRIB downregulation. In the present study, we investigated the function of ACVRIB in the regulation of SCC. Using CRISPR/Cas9-mediated ACVRIB-knockout and knockdown using siRNA, we found an increased capacity to proliferate, migrate, and invade upon ACRIB loss, as ACVRIB-KO cells exhibited an altered cytoskeleton and aberrant expression of E-cadherin and integrins. Based on chemical inhibitor studies, our data suggests that these effects are mediated through ACVRIB-independent signaling via downstream activation of Smad1/5/8 and MEK/ERK. Overall, we present a novel mechanism of SCC progression upon ACVRIB loss by showing that Activin A can transduce a signal in the absence of ACVRIB.

Citing Articles

The Role of SOX2 and SOX9 in Radioresistance and Tumor Recurrence.

Barbosa S, Laureano N, Wijaya Hadiwikarta W, Visioli F, Bonrouhi M, Pajdzik K Cancers (Basel). 2024; 16(2).

PMID: 38275880 PMC: 10814462. DOI: 10.3390/cancers16020439.


Potential Roles of Activin in Head and Neck Squamous Cell Carcinoma Progression and Mortality.

Buryska S, Patel K, Wuertz B, Gaffney P, Ondrey F Anticancer Res. 2023; 43(12):5299-5310.

PMID: 38030164 PMC: 11285815. DOI: 10.21873/anticanres.16733.


Activin-A impairs CD8 T cell-mediated immunity and immune checkpoint therapy response in melanoma.

Pinjusic K, Dubey O, Egorova O, Nassiri S, Meylan E, Faget J J Immunother Cancer. 2022; 10(5).

PMID: 35580932 PMC: 9125758. DOI: 10.1136/jitc-2022-004533.

References
1.
Armes N, Smith J . The ALK-2 and ALK-4 activin receptors transduce distinct mesoderm-inducing signals during early Xenopus development but do not co-operate to establish thresholds. Development. 1997; 124(19):3797-804. DOI: 10.1242/dev.124.19.3797. View

2.
Wijayarathna R, de Kretser D . Activins in reproductive biology and beyond. Hum Reprod Update. 2016; 22(3):342-57. DOI: 10.1093/humupd/dmv058. View

3.
Loomans H, Andl C . Intertwining of Activin A and TGFβ Signaling: Dual Roles in Cancer Progression and Cancer Cell Invasion. Cancers (Basel). 2015; 7(1):70-91. PMC: 4381251. DOI: 10.3390/cancers7010070. View

4.
Ashby W, Wikswo J, Zijlstra A . Magnetically attachable stencils and the non-destructive analysis of the contribution made by the underlying matrix to cell migration. Biomaterials. 2012; 33(33):8189-203. PMC: 3444626. DOI: 10.1016/j.biomaterials.2012.07.018. View

5.
Andl C, Fargnoli B, Okawa T, Bowser M, Takaoka M, Nakagawa H . Coordinated functions of E-cadherin and transforming growth factor beta receptor II in vitro and in vivo. Cancer Res. 2006; 66(20):9878-85. PMC: 2996096. DOI: 10.1158/0008-5472.CAN-05-4157. View